Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.54 +6.2%	$1.40	$1.05 ▼ $5.17	$157.01M	0.38	1.20 million shs	622,965 shs
FPRX Five Prime Therapeutics	$38.00	$37.94	$2.61 ▼ $38.90	$1.77B	4.4	1.98 million shs	N/A
LXRX Lexicon Pharmaceuticals	$1.07 +16.7%	$0.73	$0.28 ▼ $2.45	$331.34M	1.13	6.87 million shs	7.69 million shs
PAHC Phibro Animal Health	$31.39 +4.2%	$24.06	$16.16 ▼ $31.53	$1.22B	0.75	218,752 shs	469,142 shs
SNDX Syndax Pharmaceuticals	$9.24 +5.6%	$10.21	$8.58 ▼ $25.07	$752.91M	0.7	1.85 million shs	3.13 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+6.21%	+6.21%	+3.36%	+42.59%	+22.22%
FPRX Five Prime Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
LXRX Lexicon Pharmaceuticals	+16.74%	+16.82%	+43.60%	+116.03%	-33.13%
PAHC Phibro Animal Health	+4.22%	+12.35%	+29.55%	+77.14%	+83.14%
SNDX Syndax Pharmaceuticals	+5.60%	+2.67%	-16.68%	-12.17%	-59.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4013 of 5 stars	3.6	2.0	0.0	0.0	2.0	1.7	0.6
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.7188 of 5 stars	3.2	3.0	0.0	0.0	2.2	2.5	0.6
PAHC Phibro Animal Health	3.6762 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5
SNDX Syndax Pharmaceuticals	3.1623 of 5 stars	3.5	1.0	0.0	4.4	1.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	530.80% Upside
FPRX Five Prime Therapeutics	0.00	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	242.68% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-22.27% Downside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$35.80	287.45% Upside

Current Analyst Ratings Breakdown

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	8.91	N/A	N/A	$1.44 per share	1.07
FPRX Five Prime Therapeutics	$14.87M	119.01	N/A	N/A	$4.13 per share	9.20
LXRX Lexicon Pharmaceuticals	$31.08M	12.45	N/A	N/A	$0.40 per share	2.68
PAHC Phibro Animal Health	$1.02B	1.25	$2.20 per share	14.25	$6.34 per share	4.95
SNDX Syndax Pharmaceuticals	$23.68M	33.58	N/A	N/A	$3.38 per share	2.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
FPRX Five Prime Therapeutics	-$137.20M	-$3.92	N/A	N/A	N/A	-554.71%	-75.84%	-49.08%	N/A
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	40.24	14.95	0.50	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	N/A	N/A	N/A	$1.34 million	N/A
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.53%	N/A	61.54%	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ACRS, LXRX, SNDX, FPRX, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
FPRX Five Prime Therapeutics	N/A	5.35	5.35
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22
PAHC Phibro Animal Health	2.67	2.91	1.23
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
FPRX Five Prime Therapeutics	67.28%
LXRX Lexicon Pharmaceuticals	74.70%
PAHC Phibro Animal Health	99.34%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
FPRX Five Prime Therapeutics	6.40%
LXRX Lexicon Pharmaceuticals	13.90%
PAHC Phibro Animal Health	50.07%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
FPRX Five Prime Therapeutics	87	46.57 million	N/A	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

ACRS, LXRX, SNDX, FPRX, and PAHC Headlines

Recent News About These Companies

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?

July 9 at 3:39 PM | marketbeat.com

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

July 9 at 5:32 AM | msn.com $https://www.msn.com/en-us/money/general/syndax-s-revuforj-granted-fda-priority-review-for-relapsed-refractory-mutant-npm1-aml/ar-AA1IeAsC$

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

July 8 at 5:18 AM | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26, 2025 | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25, 2025 | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 24, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/24/3104643/0/en/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

Syndax reports publication of revumenib data from BEAT AML trial

June 13, 2025 | msn.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

June 13, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?

June 12, 2025 | marketbeat.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12, 2025 | thepharmaletter.comT

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12, 2025 | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/12/3098182/0/en/syndax-presents-new-revuforj-revumenib-data-in-relapsed-refractory-mnpm1-and-nup98r-acute-leukemia-from-augment-101-trial-at-eha-2025.html$

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, LXRX, SNDX, FPRX, and PAHC Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.54 +0.09 (+6.21%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.59 +0.05 (+3.51%)

As of 07/9/2025 08:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.07 +0.15 (+16.74%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.06 -0.02 (-1.40%)

As of 07/9/2025 07:57 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Phibro Animal Health NASDAQ:PAHC

$31.39 +1.27 (+4.22%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$31.00 -0.39 (-1.24%)

As of 07/9/2025 07:56 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.24 +0.49 (+5.60%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$9.24 -0.01 (-0.05%)

As of 07/9/2025 07:55 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time